6.80
6.80 (0%)
As of Feb 14, 2025
Coya Therapeutics, Inc. [COYA]
Source:
Company Overview
Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4 CD25high hFOXP3 cells that suppress inflammatory responses.
| Country | United States |
| Headquarters | houston, texas |
| Phone Number | (800) 587-8170 |
| Industry | manufacturing |
| CEO | Howard Berman |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $3.6 |
| Operating Profit | $-17.2 |
| Net Income | $-14.9 |
| Net Cash | $5.7 |
Profit Ratios
| Gross Margin | $3.6 |
| Operating Margin | -485.4 |
| Profit as % of Revenues | -23.9% |
| Profit as % of Assets | -34.8% |
| Profit as % of Stockholder Equity | -37.6% |
Management Effectiveness
| Return on Equity | -37.6% |
| Return on Assets | -33.6% |
| Turnover Ratio | 8.3% |
| EBITA | $-17.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $44.3 |
| Total Liabilities | $4.8 |
| Operating Cash Flow | $-10.3 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $16 |
